Malignant mixed tumours have a poor prognosis that is deemed unpredictable due to its spread being lymphatic or blood-borne. As there have only been a limited number of cases that have been reported, prognostic points are challenging to confirm, however mainly "include size, histological type, lymph node involvement, and distant metastasis" (Garcia, Atun, and Fernando, 2016). The outcome of the prognosis is dependent on early diagnosis and complete resection. The standard duration between diagnosis and reappearance was "23 months, 50 months, and 66 months for local recurrence, nodal metastasis, and distant metastasis, respectively" (Watarai, Amoh, Aki, Takasu, Katsuoka, 2011). In terms of prognosis regarding recorded patients, "27% of patients died from their disease."(Tural, Selçukbiricik, Günver, Karışmaz, and Serdengecti, 2013) As early as "nine weeks"( Malik, Saxena, and Kamath, 2013) succeeding clinical surgeries, had reports of patients' deaths been recorded. It has also been recorded that "one patient survived twelve years after their diagnosis."(Ka, Gnangnon, and Diouf, 2016) The tumour has a "60% rate of metastasis and mortality in the order of 25%" (Ka, Gnangnon, and Diouf, 2016) with the highest recordings of metastases being found in "lymph nodes and lung and less commonly, bone and brain." (Ka, Gnangnon, and Diouf, 2016)
Malignant chondroid syringoma
Neural fibrolipoma
Aggressive angiomyxoma
Malignant acrospiroma
Chondroid syringoma
Peripheral ossifying fibroma
Malignant ectomesenchymoma
Ganglion cyst